



10-25-06

07 C \$

Express Mail No. EV913329316US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Dall'Acqua et al.

U.S. Patent No.: 7,083,784 B2

Application No.: 10/020,354

Issue Date: August 1, 2006

Filed: December 12, 2001

For: MOLECULES WITH
EXTENDED HALF-LIVES,
COMPOSITIONS AND
USES THEREOF

Attorney Docket No: 10271-027

REQUEST FOR A CERTIFICATE OF CORRECTION

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentee hereby requests the issuance of a Certificate of Correction under 37 C.F.R. § 1.323 for the above-identified patent. The errors listed below, and on the enclosed Form PTO-1050, submitted herewith, are as follows:

On the front page, please correct the assignee to read as follows:

(73) Assignee: MedImmune, Inc., Gaithersburg, MD (US); Board of Regents, The University of Texas System, Austin, TX (US)

Please amend column 133, line 14 so that claim 19 reads as follows:

19. The modified IgG of claim 1, 2, 3, 4, 6, 7, 15 or 16 which immunospecifically binds to an RSV antigen.

When the Issue Fee Transmittal for Application Serial No. 10/020,354 was filed on March 10, 2006, the Board of Regents, The University of Texas System was inadvertently omitted as the co-assignee in the assignee information space provided in the Issue Fee Transmittal form. As a result, the patent issued incorrectly naming MedImmune, Inc. as the sole assignee. A Request Under 37 C.F.R. § 3.81(b) to Correct Assignee is submitted herewith.

11/09/2007 CKHLOK 00000020 503013 7083784

01 FC:1811

100.00 DA

NYJD: 1613743.1NYJD-1635201v1

BEST AVAILABLE COPY

Additionally, the text of claim 19 differs between the published patent and the last amendment filed. In particular, the word "immunospecifically" in claim 19, which was spelled correctly in the last amendment filed on March 10, 2006, is incorrectly spelled in the published patent as "inimunospecifically".

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent to correctly identify MedImmune, Inc. and the Board of Regents, The University of Texas System, as co-assignees of the patent. In addition, it is respectfully requested that claim 19 be amended to replace the misspelled word "inimunospecifically" with "immunospecifically".

The fee due for this request under 37 C.F.R. § 1.20(a) is estimated to be \$100.00. The Commissioner is hereby authorized to charge such fee, and any other fee that may be required in connection with this request, to Jones Day Deposit Account 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 23, 2006

Anthony M. Insogna (Reg. No.)
Anthony M. Insogna 35,203
JONES DAY
222 East 41st Street
New York, NY 10017
(212) 326-3939

Enclosures

By: Jennifer J. Chiodo
Reg. No. 46,417